187 related articles for article (PubMed ID: 28691538)
21. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
[No Abstract] [Full Text] [Related]
22. Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.
Jones RL; Mo G; Baldwin JR; Peterson PM; Ilaria RL; Conti I; Cronier DM; Tap WD
Cancer Chemother Pharmacol; 2019 Jan; 83(1):191-199. PubMed ID: 30406840
[TBL] [Abstract][Full Text] [Related]
23. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
Mo G; Baldwin JR; Luffer-Atlas D; Ilaria RL; Conti I; Heathman M; Cronier DM
Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.
Chiorean EG; Sweeney C; Youssoufian H; Qin A; Dontabhaktuni A; Loizos N; Nippgen J; Amato R
Cancer Chemother Pharmacol; 2014 Mar; 73(3):595-604. PubMed ID: 24452395
[TBL] [Abstract][Full Text] [Related]
25. Developments in the management of advanced soft-tissue sarcoma - olaratumab in context.
Moroncini G; Maccaroni E; Fiordoliva I; Pellei C; Gabrielli A; Berardi R
Onco Targets Ther; 2018; 11():833-842. PubMed ID: 29497315
[TBL] [Abstract][Full Text] [Related]
26. Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma.
Martin-Liberal J; Pérez E; García Del Muro X
Expert Opin Investig Drugs; 2019 Jan; 28(1):39-50. PubMed ID: 30513001
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
Striefler JK; Brandes F; Baur A; Pfitzner BM; Kaul D; Rau D; Dörr A; Schmiester M; Koulaxouzidis G; Bullinger L; Märdian S; Flörcken A
BMC Cancer; 2020 Jan; 20(1):68. PubMed ID: 31996176
[TBL] [Abstract][Full Text] [Related]
28. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
Nakano K; Takahashi S
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510588
[TBL] [Abstract][Full Text] [Related]
29. Olaratumab Approved for Soft-Tissue Sarcoma.
Cancer Discov; 2016 Dec; 6(12):1297. PubMed ID: 27827816
[TBL] [Abstract][Full Text] [Related]
30. Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas.
Song EJ; Ashcraft KA; Lowery CD; Mowery YM; Luo L; Ma Y; Campos LDS; Cardona DM; Stancato L; Kirsch DG
EBioMedicine; 2019 Feb; 40():224-230. PubMed ID: 30711517
[TBL] [Abstract][Full Text] [Related]
31. Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor.
Martin-Broto J; Hindi N
Curr Opin Oncol; 2016 Jul; 28(4):338-44. PubMed ID: 27166665
[TBL] [Abstract][Full Text] [Related]
32. Olaratumab (Lartruvo) for soft-tissue sarcoma.
Med Lett Drugs Ther; 2017 Aug; 59(1527):e138-e139. PubMed ID: 28787747
[No Abstract] [Full Text] [Related]
33. Advances of systemic treatment for adult soft-tissue sarcoma.
Liu W; Jiang Q; Zhou Y
Chin Clin Oncol; 2018 Aug; 7(4):42. PubMed ID: 30173532
[TBL] [Abstract][Full Text] [Related]
34. PDGFRA Antibody for Soft Tissue Sarcoma.
Klug LR; Heinrich MC
Cell; 2017 Feb; 168(4):555. PubMed ID: 28187274
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of olaratumab in Japanese patients with advanced solid tumors.
Doi T; Ma Y; Dontabhaktuni A; Nippgen C; Nippgen J; Ohtsu A
Cancer Sci; 2014 Jul; 105(7):862-9. PubMed ID: 24816152
[TBL] [Abstract][Full Text] [Related]
36. Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma.
Moore DC; Lavery LA
J Adv Pract Oncol; 2018 Mar; 9(2):235-240. PubMed ID: 30588358
[TBL] [Abstract][Full Text] [Related]
37. Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland.
Gennatas S; Chamberlain F; Carter T; Slater S; Cojocaru E; Lambourn B; Stansfeld A; Todd R; Verrill M; Ali N; Jones RL; Simmonds P; Keay N; McCarty H; Strauss S; Karavasilis V; Dileo P; Benson C
Clin Sarcoma Res; 2020; 10():9. PubMed ID: 32391141
[TBL] [Abstract][Full Text] [Related]
38. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
Demetri GD; Le Cesne A; Chawla SP; Brodowicz T; Maki RG; Bach BA; Smethurst DP; Bray S; Hei YJ; Blay JY
Eur J Cancer; 2012 Mar; 48(4):547-63. PubMed ID: 22240283
[TBL] [Abstract][Full Text] [Related]
39. Advances and controversies in the management of soft tissue sarcomas.
Demetri GD; Blay JY; Casali PG
Future Oncol; 2017 Jan; 13(1s):3-11. PubMed ID: 27918199
[TBL] [Abstract][Full Text] [Related]
40. Newer therapeutic strategies for soft-tissue sarcomas.
Bourcier K; Italiano A
Pharmacol Ther; 2018 Aug; 188():118-123. PubMed ID: 29481809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
